Cancer company Peloton raises $52.4M

Peloton Therapeutics Inc. (Dallas, Texas) raised $52.4 million in a series D round. New investor Foresite Capital Management participated, as did all of Peloton's existing investors, including Remeditex, The Column Group (TCG), Tichenor Ventures, Topspin Fund and Nextech Invest.

Peloton's lead program, PT2385, is in a dose-escalating Phase I study to treat advanced clear cell renal cell carcinoma (ccRCC). At the American Society of Clinical Oncology meeting in June, Peloton said a range of PT2385 doses led to one complete response and three partial responses, plus 16 cases of stable disease lasting at least 16 weeks, among 51 patients. ...